Gene · 150094
Papers4,535
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 4,535
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clinical factors for choosing active surveillance: an analysis of papillary thyroid microcarcinoma patients with recurrence. | Eur Thyroid J | 2023 | 37992297 | PubTator, text mining | PubMed |
| Computational exploration of novel ROCK2 inhibitors for cardiovascular disease management; insights from high-throughput virtual screening, molecular docking, DFT and MD simulation. | PLoS One | 2023 | 37972144 | PubTator, text mining | PubMed |
| LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition. | EMBO Mol Med | 2023 | 37966164 | PubTator, text mining | PubMed |
| A 15-Gene-Based Risk Signature for Predicting Overall Survival in SCLC Patients Who Have Undergone Surgical Resection. | Cancers (Basel) | 2023 | 37958393 | PubTator, text mining | PubMed |
| Correlation Analyses between Histological Staging and Molecular Alterations in Tumor-Derived and Cell-Free DNA of Early-Stage Primary Cutaneous Melanoma. | Cancers (Basel) | 2023 | 37958315 | PubTator, text mining | PubMed |
| Kinesin family member 18B activates mTORC1 signaling via actin gamma 1 to promote the recurrence of human hepatocellular carcinoma. | Oncogenesis | 2023 | 37957153 | PubTator, text mining | PubMed |
| Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases. | Signal Transduct Target Ther | 2023 | 37953273 | PubTator, text mining | PubMed |
| Novel RICTOR amplification harbouring entities: FISH validation of RICTOR amplification in tumour tissue after next-generation sequencing. | Sci Rep | 2023 | 37949943 | PubTator, text mining | PubMed |
| Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6. | J Ovarian Res | 2023 | 37940982 | PubTator, text mining | PubMed |
| A robust six-gene prognostic signature based on two prognostic subtypes constructed by chromatin regulators is correlated with immunological features and therapeutic response in lung adenocarcinoma. | Aging (Albany NY) | 2023 | 37938151 | PubTator, text mining | PubMed |
| The m6A/m1A/m5C-Related Methylation Modification Patterns and Immune Landscapes in Rheumatoid Arthritis and Osteoarthritis Revealed by Microarray and Single-Cell Transcriptome. | J Inflamm Res | 2023 | 37933335 | PubTator, text mining | PubMed |
| Advances in thermoelectric AgBiSe2: Properties, strategies, and future challenges. | Heliyon | 2023 | 37928035 | PubTator, text mining | PubMed |
| Determining the prognosis of Lung cancer from mutated genes using a deep learning survival model: a large multi-center study. | Cancer Cell Int | 2023 | 37925409 | PubTator, text mining | PubMed |
| Virulence genotype and phenotype of two clinical isolates of Arcobacter butzleri obtained from patients with different pathologies. | Arch Microbiol | 2023 | 37923944 | PubTator, text mining | PubMed |
| PRO-IP-seq tracks molecular modifications of engaged Pol II complexes at nucleotide resolution. | Nat Commun | 2023 | 37923726 | PubTator, text mining | PubMed |
| Comparative transcriptome analysis of dioecious floral development in Trachycarpus fortunei using Illumina and PacBio SMRT sequencing. | BMC Plant Biol | 2023 | 37919651 | PubTator, text mining | PubMed |
| Blocking salt-inducible kinases with YKL-06-061 prevents PTZ-induced seizures in mice. | Brain Behav | 2023 | 37919236 | PubTator, text mining | PubMed |
| Real-world impact of the fixed-dose combination on improving treatment outcomes of drug-susceptible tuberculosis: a comparative study using multiyear national tuberculosis patient data. | BMJ Open Respir Res | 2023 | 37918950 | PubTator, text mining | PubMed |
| The Cyclin-dependent kinase 1: more than a cell cycle regulator. | Br J Cancer | 2023 | 37898722 | PubTator, text mining | PubMed |
| Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing. | Nat Commun | 2023 | 37898613 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/150094/papers?page=16